The Trump administration's Department of Justice issued a final order on April 22, 2026, rescheduling FDA-approved cannabis products and state-licensed medical marijuana from Schedule I to Schedule III under the Controlled Substances Act, effective upon Federal Register publication around April 28. This executive action, signed by Acting Attorney General Todd Blanche, unlocks federal protections and tax benefits like Section 280E relief for qualifying medical operations, with the DEA now accepting registration applications as of late April. Broader rescheduling of botanical marijuana awaits an expedited DEA administrative hearing starting June 29, 2026, amid ongoing GOP congressional efforts to block further changes despite the administration's move. Traders weigh procedural timelines, potential legal challenges, and political pressures in assessing resolution paths.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated$750,045 Vol.
June 30
4%
December 31
36%
$750,045 Vol.
June 30
4%
December 31
36%
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Market Opened: Feb 7, 2026, 5:04 PM ET
Resolver
0x65070BE91...The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Resolver
0x65070BE91...The Trump administration's Department of Justice issued a final order on April 22, 2026, rescheduling FDA-approved cannabis products and state-licensed medical marijuana from Schedule I to Schedule III under the Controlled Substances Act, effective upon Federal Register publication around April 28. This executive action, signed by Acting Attorney General Todd Blanche, unlocks federal protections and tax benefits like Section 280E relief for qualifying medical operations, with the DEA now accepting registration applications as of late April. Broader rescheduling of botanical marijuana awaits an expedited DEA administrative hearing starting June 29, 2026, amid ongoing GOP congressional efforts to block further changes despite the administration's move. Traders weigh procedural timelines, potential legal challenges, and political pressures in assessing resolution paths.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated



Beware of external links.
Beware of external links.
Frequently Asked Questions